Literature DB >> 26855980

Quetiapine's effect on the SCL-90-R domains in patients with borderline personality disorder.

Susanne S Lee1, Jeff Allen, Donald W Black, Mary C Zanarini, S Charles Schulz.   

Abstract

BACKGROUND: This study aimed to examine the impact of quetiapine on the symptom and distress domains measured by the Symptom Checklist-90-Revised (SCL-90-R) in patients with borderline personality disorder (BPD).
METHODS: Ninety-five participants meeting DSM-IV diagnostic criteria for BPD were randomly assigned to low-dosage (quetiapine, 150 mg/d; n = 33), moderate-dosage (quetiapine, 300 mg/d; n = 33), or placebo (n = 29). SCL-90-R was administered weekly over the course of an 8-week double-blind treatment phase. We used a mixed-effects model to analyze subscale scores of the SCL-90-R.
RESULTS: Results showed that both dosages of quetiapine were effective in reducing levels of overall psychological distress, interpersonal sensitivity, depression, and hostility compared with those who received placebo.
CONCLUSIONS: SCL-90-R can be a useful tool that would allow clinicians to collect information in addition to the DSM symptoms to better understand the diagnostic heterogeneity found in patients diagnosed with BPD.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26855980

Source DB:  PubMed          Journal:  Ann Clin Psychiatry        ISSN: 1040-1237            Impact factor:   1.567


  3 in total

Review 1.  Pharmacotherapy for Borderline Personality Disorder: an Update of Published, Unpublished and Ongoing Studies.

Authors:  Jutta Stoffers-Winterling; Ole Jakob Storebø; Klaus Lieb
Journal:  Curr Psychiatry Rep       Date:  2020-06-05       Impact factor: 5.285

2.  Psychological Status of Volunteers in a Phase I Clinical Trial Assessed by Symptom Checklist 90 (SCL-90) and Eysenck Personality Questionnaire (EPQ).

Authors:  Yudong Wei; Haiyan Li; Huali Wang; Shuang Zhang; Yumei Sun
Journal:  Med Sci Monit       Date:  2018-07-17

Review 3.  Current Clinical Psychopharmacology in Borderline Personality Disorder.

Authors:  Antonio Del Casale; Luca Bonanni; Paride Bargagna; Francesco Novelli; Federica Fiaschè; Marco Paolini; Francesca Forcina; Gaia Anibaldi; Francesca Natalia Cortese; Alessia Iannuccelli; Barbara Adriani; Roberto Brugnoli; Paolo Girardi; Joel Paris; Maurizio Pompili
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.